2
RESEARCH METHODOLOGY
35
5
MARKET OVERVIEW
Emerging markets and innovative drug technologies drive vision disorder treatment advancements.
54
5.2.1.1
AGING POPULATION AND GROWING PREVALENCE OF VISION DISORDERS
5.2.1.2
STRONG DRUG PIPELINE AND GROWING INNOVATION EFFORTS
5.2.1.3
INCREASING INVESTMENTS AND STRATEGIC COLLABORATIONS
5.2.1.4
IMPROVED REIMBURSEMENT POLICIES
5.2.2.1
OFF-LABEL DRUG USE FOR VARIOUS INDICATIONS
5.2.3.1
SHIFTING FOCUS ON NEW DRUG MODALITIES
5.2.3.2
EXPANSION INTO EMERGING MARKETS
5.2.4.1
FREQUENT AND INCONVENIENT INTRAVITREAL INJECTIONS LEADING TO PATIENT NON-ADHERENCE TO TREATMENT
5.3.1.1
HYBRIDOMA TECHNOLOGY
5.3.1.2
RECOMBINANT DNA TECHNOLOGY
5.3.1.3
ANTIBODY ENGINEERING
5.3.2
ADJACENT TECHNOLOGIES
5.3.2.1
OPTOGENETIC TECHNOLOGY
5.3.2.2
DRUG-RELEASE TECHNOLOGIES
5.3.2.3
OCULAR IMPLANT TECHNOLOGIES
5.3.3
COMPLEMENTARY TECHNOLOGIES
5.3.3.1
3D PRINTING AND BIOPRINTING
5.3.3.2
OCULAR IMAGING TECHNOLOGIES
5.4
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5.1
INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
5.5.2
INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
5.5.3
INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
5.7.1
OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS
5.7.2
OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
5.7.3
OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS
5.7.4
OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES
5.9.1
REGULATORY LANDSCAPE
5.9.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10
PORTER’S FIVE FORCES ANALYSIS
5.10.1
INTENSITY OF COMPETITIVE RIVALRY
5.10.2
BARGAINING POWER OF SUPPLIERS
5.10.3
BARGAINING POWER OF BUYERS
5.10.4
THREAT OF SUBSTITUTES
5.10.5
THREAT OF NEW ENTRANTS
5.11
KEY CONFERENCES & EVENTS, 2025–2026
5.12
REIMBURSEMENT SCENARIO
5.13
KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1
BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS
5.14
INVESTMENT & FUNDING SCENARIO
5.16
IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET
5.16.1
CHALLENGES IN DRUG DISCOVERY
5.16.2
IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS
5.17
IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET
5.17.2
PRICE IMPACT ANALYSIS
5.17.3
KEY IMPACT ON VARIOUS REGIONS
5.17.4
MANUFACTURING INDUSTRY IMPACT
5.17.4.1
OPHTHALMOLOGY DRUG MANUFACTURERS
6
OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 25 Data Tables
98
6.2.1
HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH
6.3.1
GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH
6.4.1
CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION
7
OPHTHALMOLOGY DRUGS MARKET, BY MODALITY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
112
7.2
MONOCLONAL ANTIBODIES & FUSION PROTEINS
7.2.1
GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET
7.3.1
INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET
8
OPHTHALMOLOGY DRUGS MARKET, BY INDICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 30 Data Tables
123
8.2
AGE-RELATED MACULAR DEGENERATION
8.2.1
WET AGE-RELATED MACULAR DEGENERATION
8.2.1.1
INCREASING DEMAND FOR EFFECTIVE THERAPIES TO DRIVE MARKET
8.2.2
DRY AGE-RELATED MACULAR DEGENERATION
8.2.2.1
LARGE MARKET OPPORTUNITY FOR INNOVATION TO DRIVE GROWTH
8.3
DIABETIC RETINOPATHY (DR)
8.3.1
FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES
8.4
DIABETIC MACULAR EDEMA (DME)
8.4.1
GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME TO DRIVE MARKET
9
OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
139
9.2.1
HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET
9.3.1
EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS
9.4
OTHER ROUTES OF ADMINISTRATION
10
OPHTHALMOLOGY DRUGS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
148
10.2.1
GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH
10.3
LONG-TERM CARE FACILITIES
10.3.1
NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
10.4.1
RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH
11
OPHTHALMOLOGY DRUGS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 14 Countries | 161 Data Tables.
158
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2.1
RISING INVESTMENTS IN HEALTHCARE RESEARCH AND DEVELOPMENT TO SUPPORT GROWTH
11.2.3.1
RISING GOVERNMENT INITIATIVES TO SUPPORT OPHTHALMOLOGY DRUGS RESEARCH AND INCREASING DRUG APPROVALS TO SUPPORT GROWTH
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2.1
RISING FOCUS ON CLINICAL RESEARCH TO DRIVE MARKET
11.3.3.1
ONGOING ADVANCEMENTS IN TECHNOLOGY TO DRIVE MARKET GROWTH
11.3.4.1
GROWING INVESTMENTS AND GOVERNMENT SUPPORT TO DRIVE MARKET GROWTH
11.3.5.1
GROWING INVESTMENTS AND RESEARCH TO SUPPORT MARKET
11.3.6.1
GROWING GERIATRIC POPULATION TO DRIVE MARKET GROWTH
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2.1
LARGE DIABETIC POPULATION TO BOOST MARKET
11.4.3.1
GROWING AGING POPULATION TO INTENSIFY DEMAND FOR EFFECTIVE TREATMENTS
11.4.4.1
INCREASING DIABETIC CASES, GOVERNMENT SUPPORT, AND GROWING AVAILABILITY OF BIOSIMILARS TO SUPPORT MARKET
11.4.5.1
STRONG BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH
11.4.6.1
STRONG R&D PIPELINE AND INCREASING FOCUS ON RESEARCH TO SUPPORT GROWTH
11.4.7
REST OF ASIA PACIFIC
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2.1
SIGNIFICANT RATES OF VISUAL IMPAIRMENT IN REGION TO DRIVE DEMAND FOR ADVANCED TREATMENTS
11.5.3.1
GROWING RESEARCH INITIATIVES AND INNOVATIONS TO SUPPORT MARKET GROWTH
11.5.4
REST OF LATIN AMERICA
11.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2.1
GROWING RESEARCH INITIATIVES AND IMPROVING HEALTHCARE INFRASTRUCTURE TO SUPPORT GROWTH
11.6.3
REST OF MIDDLE EAST
11.7.1
GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH
11.7.2
MACROECONOMIC OUTLOOK FOR AFRICA
12
COMPETITIVE LANDSCAPE
Discover top strategies and rising stars shaping the ophthalmology drugs market.
237
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
12.3
REVENUE ANALYSIS, 2022–2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024
12.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1
COMPANY FOOTPRINT
12.5.5.2
REGION FOOTPRINT
12.5.5.3
MOLECULE FOOTPRINT
12.5.5.4
MODALITY FOOTPRINT
12.5.5.5
INDICATION FOOTPRINT
12.6
COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
12.6.1
PROGRESSIVE COMPANIES
12.6.2
RESPONSIVE COMPANIES
12.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
12.6.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
12.7
COMPANY VALUATION & FINANCIAL METRICS
12.7.1
VALUATION OF KEY PLAYERS
12.7.2
FINANCIAL METRICS OF KEY PLAYERS
12.8
BRAND/PRODUCT COMPARISON
12.9
COMPETITIVE SCENARIO
12.9.1
PRODUCT LAUNCHES & APPROVALS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
257
13.1.1
REGENERON PHARMACEUTICALS INC.
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
PRODUCTS OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.2
F. HOFFMANN-LA ROCHE LTD.
13.1.6
APELLIS PHARMACEUTICALS
13.1.9
ASTELLAS PHARMA INC.
13.1.13
SANTEN PHARMACEUTICAL CO., LTD.
13.1.15
OUTLOOK THERAPEUTICS, INC.
13.1.16
TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.2
OTHER PLAYERS (PIPELINE COMPANIES)
13.2.1
OCULAR THERAPEUTIX, INC.
13.2.3
KODIAK SCIENCES INC.
13.2.4
EYEPOINT PHARMACEUTICALS, INC.
13.2.6
CLEARSIDE BIOMEDICAL
13.2.7
SHANGHAI HENLIUS BIOTECH, INC.
13.2.8
ADVERUM BIOTECHNOLOGIES, INC.
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
TABLE 1
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 2
OPHTHALMOLOGY DRUGS MARKET: RISK ANALYSIS
TABLE 3
OPHTHALMOLOGY DRUGS MARKET: IMPACT ANALYSIS
TABLE 4
INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
TABLE 5
INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
TABLE 6
OPHTHALMOLOGY DRUGS MARKET: LIST OF RAW MATERIAL SUPPLIERS
TABLE 7
OPHTHALMOLOGY DRUGS MARKET: LIST OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
TABLE 8
OPHTHALMOLOGY DRUGS MARKET: LIST OF END USERS
TABLE 9
OPHTHALMOLOGY DRUGS MARKET: LIST OF REGULATORY AUTHORITIES
TABLE 10
OPHTHALMOLOGY DRUGS MARKET: INDICATIVE LIST OF PATENTS, 2024
TABLE 11
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16
OPHTHALMOLOGY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 17
OPHTHALMOLOGY DRUGS MARKET: LIST OF CONFERENCES & EVENTS
TABLE 18
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 19
BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS, BY END USER
TABLE 20
OPHTHALMOLOGY DRUGS IN CLINICAL PIPELINE, PHASE III (AS OF APRIL 2025)
TABLE 21
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 22
EXPORTS AND IMPORTS, BY REGION
TABLE 23
OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 24
OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2030 (USD MILLION)
TABLE 25
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 26
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 27
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 28
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2030 (USD MILLION)
TABLE 30
OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023–2030 (USD MILLION)
TABLE 31
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 34
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023–2030 (USD MILLION)
TABLE 36
OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023–2030 (USD MILLION)
TABLE 37
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023–2030 (USD MILLION)
TABLE 42
OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 43
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 48
OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 49
OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION)
TABLE 50
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION)
TABLE 55
OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 56
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 61
OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 62
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 67
OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 68
OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 69
OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 70
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 75
OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 76
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 81
OPHTHALMOLOGY DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 82
OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2023–2030 (USD MILLION)
TABLE 83
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION)
TABLE 86
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 89
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION)
TABLE 91
OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 92
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 96
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 97
OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 98
OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 99
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 104
OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 105
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 110
OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 111
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 116
OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 117
OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 118
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 123
OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 124
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 129
OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 130
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 132
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 135
OPHTHALMOLOGY DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 136
NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 137
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 139
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 140
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 141
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 142
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 143
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 144
US: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 145
US: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 146
US: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 147
US: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 148
US: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 149
US: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 150
CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 151
CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 152
CANADA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 153
CANADA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 154
CANADA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 155
CANADA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 156
EUROPE: MACROECONOMIC INDICATORS
TABLE 157
EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158
EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 159
EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 160
EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 161
EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 162
EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 163
EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 164
GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 165
GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 166
GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 167
GERMANY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 168
GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 169
GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 170
UK: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 171
UK: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 172
UK: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 173
UK: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 174
UK: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 175
UK: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 176
FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 177
FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 178
FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 179
FRANCE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 180
FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 181
FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 182
ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 183
ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 184
ITALY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 185
ITALY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 186
ITALY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 187
ITALY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 188
SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 189
SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 190
SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 191
SPAIN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 192
SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 193
SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 194
REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 195
REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 196
REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 197
REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 198
REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 199
REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 200
ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 201
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 203
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 204
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 205
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 206
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 207
ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 208
CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 209
CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 210
CHINA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 211
CHINA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 212
CHINA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 213
CHINA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 214
JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 215
JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 216
JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 217
JAPAN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 218
JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 219
JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 220
INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 221
INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 222
INDIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 223
INDIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 224
INDIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 225
INDIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 226
AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 227
AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 228
AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 229
AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 230
AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 231
AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 232
SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 233
SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 234
SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 235
SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 236
SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 237
SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 238
REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 239
REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 240
REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 241
REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 242
REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 243
REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 244
LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 245
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 246
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 247
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 248
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 249
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 250
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 251
LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 252
BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 253
BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 254
BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 255
BRAZIL: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 256
BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 257
BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 258
MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 259
MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 260
MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 261
MEXICO: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 262
MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 263
MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 264
REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 265
REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 266
REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 267
REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 268
REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 269
REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 270
MIDDLE EAST: MACROECONOMIC INDICATORS
TABLE 271
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 272
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 273
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 274
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 275
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 276
MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 277
GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 278
GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 279
GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 280
GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 281
GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 282
GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 283
REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 284
REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 285
REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 286
REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 287
REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 288
REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 289
AFRICA: MACROECONOMIC INDICATORS
TABLE 290
AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 291
AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
TABLE 292
AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
TABLE 293
AFRICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
TABLE 294
AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 295
AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 296
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
TABLE 297
OPHTHALMOLOGY DRUGS MARKET: DEGREE OF COMPETITION
TABLE 298
OPHTHALMOLOGY DRUGS MARKET: REGION FOOTPRINT
TABLE 299
OPHTHALMOLOGY DRUGS MARKET: MOLECULE FOOTPRINT
TABLE 300
OPHTHALMOLOGY DRUGS MARKET: MODALITY FOOTPRINT
TABLE 301
OPHTHALMOLOGY DRUGS MARKET: INDICATION FOOTPRINT
TABLE 302
OPHTHALMOLOGY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 303
OPHTHALMOLOGY DRUGS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
TABLE 304
OPHTHALMOLOGY DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025
TABLE 305
OPHTHALMOLOGY DRUGS MARKET: DEALS, JANUARY 2022–MAY 2025
TABLE 306
REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
TABLE 307
REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
TABLE 308
REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
TABLE 309
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 310
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 311
F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025
TABLE 312
BAYER AG: COMPANY OVERVIEW
TABLE 313
BAYER AG: PRODUCTS OFFERED
TABLE 314
BAYER AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
TABLE 315
NOVARTIS AG: COMPANY OVERVIEW
TABLE 316
NOVARTIS AG: PRODUCTS OFFERED
TABLE 317
NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
TABLE 318
NOVARTIS AG: DEALS, JANUARY 2021–MAY 2025
TABLE 319
ABBVIE: COMPANY OVERVIEW
TABLE 320
ABBVIE: PRODUCTS OFFERED
TABLE 321
APELLIS PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 322
APELLIS PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 323
APELLIS PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
TABLE 324
APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021–MAY 2025
TABLE 325
BIOGEN: COMPANY OVERVIEW
TABLE 326
BIOGEN: PRODUCTS OFFERED
TABLE 327
BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025
TABLE 328
BAUSCH + LOMB: COMPANY OVERVIEW
TABLE 329
BAUSCH + LOMB: PRODUCTS OFFERED
TABLE 330
BAUSCH + LOMB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025
TABLE 331
ASTELLAS PHARMA INC.: COMPANY OVERVIEW
TABLE 332
ASTELLAS PHARMA INC.: PRODUCTS OFFERED
TABLE 333
ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
TABLE 334
ASTELLAS PHARMA INC.: DEALS, JANUARY 2021–JULY 2024
TABLE 335
FORMYCON AG: COMPANY OVERVIEW
TABLE 336
FORMYCON AG: PRODUCTS OFFERED
TABLE 337
FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025
TABLE 338
FORMYCON AG: DEALS, JANUARY 2021–MAY 2025
TABLE 339
BIOCON: COMPANY OVERVIEW
TABLE 340
BIOCON: PRODUCTS OFFERED
TABLE 341
BIOCON: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
TABLE 342
BIOCON: DEALS, JANUARY 2021–MAY 2025
TABLE 343
SANDOZ GROUP AG: COMPANY OVERVIEW
TABLE 344
SANDOZ GROUP AG: PRODUCTS OFFERED
TABLE 345
SANDOZ GROUP AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
TABLE 346
SANDOZ GROUP AG: DEALS, JANUARY 2021–JULY 2024
TABLE 347
SANTEN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
TABLE 348
SANTEN PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED
TABLE 349
SANTEN PHARMACEUTICAL CO., LTD: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025
TABLE 350
INNOVENT: COMPANY OVERVIEW
TABLE 351
INNOVENT: PRODUCTS OFFERED
TABLE 352
INNOVENT: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
TABLE 353
OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 354
OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 355
OUTLOOK THERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025
TABLE 356
OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2022–MAY 2025
TABLE 357
TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
TABLE 358
TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 359
TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025
TABLE 360
TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–MAY 2025
TABLE 361
OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW
TABLE 362
OPTHEA LIMITED: COMPANY OVERVIEW
TABLE 363
KODIAK SCIENCES INC.: COMPANY OVERVIEW
TABLE 364
EYEPOINT PHARMACEUTICALS, INC.: COMPANY OVERVIEW
TABLE 365
ALVOTECH: COMPANY OVERVIEW
TABLE 366
CLEARSIDE BIOMEDICAL: COMPANY OVERVIEW
TABLE 367
SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW
TABLE 368
ADVERUM BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 369
REMEGEN: COMPANY OVERVIEW
TABLE 370
SPARINGVISION: COMPANY OVERVIEW
FIGURE 1
OPHTHALMOLOGY DRUGS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
OPHTHALMOLOGY DRUGS MARKET: RESEARCH DESIGN
FIGURE 3
OPHTHALMOLOGY DRUGS MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 4
OPHTHALMOLOGY DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 5
OPHTHALMOLOGY DRUGS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 6
PRODUCT REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)
FIGURE 7
REVENUE SHARE ANALYSIS OF REGENERON PHARMACEUTICALS, INC. (2024)
FIGURE 8
OPHTHALMOLOGY DRUGS MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 9
OPHTHALMOLOGY DRUGS MARKET: BOTTOM-UP APPROACH
FIGURE 10
OPHTHALMOLOGY DRUGS MARKET: CAGR PROJECTIONS
FIGURE 11
OPHTHALMOLOGY DRUGS MARKET: DATA TRIANGULATION
FIGURE 12
OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION)
FIGURE 13
OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION)
FIGURE 14
OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
FIGURE 15
OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 16
OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 17
GEOGRAPHIC ANALYSIS: OPHTHALMOLOGY DRUGS MARKET
FIGURE 18
GROWING PREVALENCE OF RETINAL DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH
FIGURE 19
AFLIBERCEPT ACCOUNTED FOR LARGEST SHARE OF OPHTHALMOLOGY DRUGS MARKET IN NORTH AMERICA IN 2024
FIGURE 20
HOSPITALS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 21
NORTH AMERICA LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL OPHTHALMOLOGY DRUGS MARKET DURING FORECAST PERIOD
FIGURE 22
OPHTHALMOLOGY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 23
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 24
INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
FIGURE 25
OPHTHALMOLOGY DRUGS MARKET: VALUE CHAIN ANALYSIS
FIGURE 26
OPHTHALMOLOGY DRUGS MARKET: ECOSYSTEM ANALYSIS
FIGURE 27
OPHTHALMOLOGY DRUGS MARKET: PATENT PUBLICATION TRENDS, JURISDICTION, AND TOP APPLICANT ANALYSIS (JANUARY 2014–DECEMBER 2024)
FIGURE 28
OPHTHALMOLOGY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 29
KEY STAKEHOLDERS IN BUYING PROCESS OF OPHTHALMOLOGY DRUGS, BY MODALITY
FIGURE 30
KEY BUYING CRITERIA FOR END USERS
FIGURE 31
NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
FIGURE 32
EUROPE: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
FIGURE 33
REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION)
FIGURE 34
MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
FIGURE 35
OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 36
OPHTHALMOLOGY DRUGS MARKET: COMPANY FOOTPRINT
FIGURE 37
OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 38
EV/EBITDA OF KEY PLAYERS
FIGURE 39
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
FIGURE 40
OPHTHALMOLOGY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 41
REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
FIGURE 42
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
FIGURE 43
BAYER AG: COMPANY SNAPSHOT (2024)
FIGURE 44
NOVARTIS AG: COMPANY SNAPSHOT (2024)
FIGURE 45
ABBVIE: COMPANY SNAPSHOT (2024)
FIGURE 46
APELLIS PHARMACEUTICALS: COMPANY SNAPSHOT (2024)
FIGURE 47
BIOGEN: COMPANY SNAPSHOT (2024)
FIGURE 48
BAUSCH + LOMB: COMPANY SNAPSHOT (2024)
FIGURE 49
ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024)
FIGURE 50
FORMYCON AG: COMPANY SNAPSHOT (2024)
FIGURE 51
BIOCON: COMPANY SNAPSHOT (2024)
FIGURE 52
SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)
FIGURE 53
SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT (2024)
FIGURE 54
INNOVENT: COMPANY SNAPSHOT (2024)
FIGURE 55
TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
Growth opportunities and latent adjacency in Ophthalmology Drugs Market